-
Comparative Study Clinical Trial
[The use of metamizole as a risk factor in the occurrence of agranulocytosis].
- V Vlakhov, N Bakracheva, and L Popova.
- Vutr Boles. 1988 Jan 1;27(2):80-5.
AbstractThe risk of agranulocytosis following the use of metamizole was studied by the method of controlled cases. All cases of agranulocytosis and their control cases in Sofia for the period 1982-1986 were included in the study. The mean agranulocytosis morbidity for this period was 3.16 cases for one million population for one year. The etiologic fraction was 7.1%. The relative risk of agranulocytosis following the use of metamizole is 1.25, the maximal risk is 0.03 cases for one million persons using metamizole for one year and the maximal lethal risk is 0.007 cases for one million persons using metamizole for one year. The use of metamizole in Bulgaria for the same period was studied, too. The data presented as a number of defined daily doses used by 1000 population for one day show that the use of metamizole in this country is high. A tendency toward an increase of 7.3% per year was found during the investigation. At the same time the agranulocytosis morbidity remained constant during the period of investigation. The results of the study lead to the conclusion that the use of metamizole is not related to a higher risk of agranulocytosis.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:

- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.